350 results on '"Kosmider, O"'
Search Results
2. Un syndrome VEXAS chez une femme sans monosomie X
3. Efficacité et tolérance de l’azacitidine au cours du syndrome VEXAS avec et sans syndrome myélodysplasique : données du registre français
4. Efficacité et tolérance des thérapies ciblées au cours du syndrome VEXAS : étude rétrospective du groupe français VEXAS sur 110 patients
5. Caractéristiques cliniques et biologiques du syndrome VEXAS selon le sexe : comparaison de 12 femmes françaises à 274 hommes
6. Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION
7. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
8. Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ?
9. Le syndrome VEXAS se caractérise par une activation des voies de l’inflammasome dans le sang et les tissus et par une dérégulation du compartiment monocytaire
10. Caractéristiques cliniques et histologiques des manifestations cutanées du syndrome VEXAS : une étude rétrospective centralisée de 59 cas
11. Vacuoles au sein des précurseurs myéloïdes médullaires dans le syndrome VEXAS : seuil et performances diagnostiques
12. P057 - Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION
13. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
14. P029 - Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ?
15. Signification clinique des gammapathies monoclonales au cours du syndrome VEXAS
16. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
17. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
18. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
19. Utilisation de l’azacitidine dans le VEXAS chez des patients porteurs d’un syndrome myélodysplasique : données du registre Français VEXAS
20. Observatoire français de 116 patients avec un syndrome VEXAS : corrélation phénotype–génotype et prise en charge
21. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes
22. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia
23. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
24. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications
25. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages
26. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
27. ASXL1andSETBP1mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
28. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
29. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
30. Quand la génétique permet d’expliquer 14 ans de phénomènes inflammatoires
31. Quand la PAN devient VEXAS
32. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate
33. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene
34. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
35. Apport de la tomographie par émission de positrons (TEP) au cours du syndrome VEXAS
36. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
37. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias
38. Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
39. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
40. Caractéristiques cliniques et histologiques des manifestations cutanées du syndrome VEXAS : une étude rétrospective centralisée de 59 cas
41. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
42. C020 Prevalence of TET2 mutations in MDS
43. P051 TET2 is a tumor suppressor gene targeted in myeloid disorders
44. C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS
45. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia
46. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
47. 104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY
48. 148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS
49. 109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS
50. Erratum: Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.